These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36323566)

  • 21. High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men.
    Fujihara Y; Hamanoue N; Yano H; Tanabe M; Akehi Y; Nomiyama T; Yanase T
    Endocr J; 2019 Jul; 66(7):637-645. PubMed ID: 31068503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index.
    Funada K; Kusano Y; Gyotoku Y; Shirahashi R; Suda T; Tamano M
    World J Gastroenterol; 2023 Jun; 29(23):3703-3714. PubMed ID: 37398885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients.
    Hua X; Li M; Pan F; Xiao Y; Cui W; Hu Y
    Sci Rep; 2017 Nov; 7(1):14532. PubMed ID: 29109457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
    Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife.
    Sarkar M; VanWagner LB; Terry JG; Carr JJ; Rinella M; Schreiner PJ; Lewis CE; Terrault N;
    Am J Gastroenterol; 2019 May; 114(5):758-763. PubMed ID: 30730350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.
    Jiang Y; Han T; Zhang ZG; Zhang Y; Qi FX
    Rev Esp Enferm Dig; 2018 Jan; 110(1):19-24. PubMed ID: 29271227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
    Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
    PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study.
    Sugimoto K; Lee DH; Lee JY; Yu SJ; Moriyasu F; Sakamaki K; Oshiro H; Takahashi H; Kakegawa T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Choi BI; Itoi T
    Radiology; 2021 Dec; 301(3):625-634. PubMed ID: 34519576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
    Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
    Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
    Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis.
    Xin S; Zhan Q; Chen X; Xu J; Yu Y
    BMC Gastroenterol; 2020 Jun; 20(1):186. PubMed ID: 32532204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.
    Fialoke S; Malarstig A; Miller MR; Dumitriu A
    AMIA Annu Symp Proc; 2018; 2018():430-439. PubMed ID: 30815083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Serum Sex Hormone-Binding Globulin Associated with Insulin Resistance in Men with Nonalcoholic Fatty Liver Disease.
    Ye J; Yao Z; Tan A; Gao Y; Chen Y; Lin X; He R; Tang R; Hu Y; Zhang H; Yang X; Wang Q; Jiang Y; Mo Z
    Horm Metab Res; 2017 May; 49(5):359-364. PubMed ID: 28282659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction.
    Di Stasi V; Maseroli E; Rastrelli G; Scavello I; Cipriani S; Todisco T; Marchiani S; Sorbi F; Fambrini M; Petraglia F; Maggi M; Vignozzi L
    Front Endocrinol (Lausanne); 2021; 12():641446. PubMed ID: 33854482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis.
    Kayadibi H; Gültepe M; Yasar B; Ince AT; Ozcan O; Ipcioglu OM; Kurdas OO; Bolat B; Benek YZ; Guveli H; Atalay S; Ozkara S; Keskin O
    Dig Dis Sci; 2009 Aug; 54(8):1764-71. PubMed ID: 18989777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.